Skip to main content

Table 2 Baseline clinical characteristics of enrolled participants

From: The transient effect of a peer support intervention to improve adherence among adolescents and young adults failing antiretroviral therapy in Harare, Zimbabwe: a randomized control trial

  Total
N = 212
Intervention
N = 104
Standard of care
N = 108
CD4 count (cells/mm3) Median (IQR), (n =) 217 (69–392), (n = 208) 217 (95–409), (n = 101) 211 (52–381), (n = 107)
CD4 Count < 200 cells/mm3, n (%) 100 (47.2%) 48 (46.2%) 52 (48.2%)
HIV VL    
Viral load > 400 copies/mL, n (%) 192 (90.6%) 92 (88.5%) 100 (92.6%)
Viral load ≥ 1000copies/mL, n (%) 183 (86.3%) 89 (85.6%) 94 (87.0%)
Viral Load (log10 copies/mL) Median (IQR) 4.3 (3.7–4.8) 4.2 (3.6–4.7) 4.5 (3.8–4.9)
Duration on ART and self reported adherence
Duration in years on ART Median (IQR), (n =) 6.4 (3.8–8.5), (n = 211) 6.5 (3.9–8.6), (n = 104) 6.4 (3.8–8.4), (n = 107)
Self-reported adherence (95% or higher), n (%) Total N = 180
134 (74.4%)
61 (67.8%) 73 (81.1%)
ART Regimen (N = 202) (N = 101) (N = 101)
First Line ART Regimen, n (%) 142 (70.2) 69 (68.3) 73 (72.2)
Tenofovir/Lamivudine/Efavirenz 93 (46.0%) 44 (43.6%) 49 (48.5%)
Tenofovir/Lamivudine/Nevirapine 11 (5.5%) 5 (5.0%) 6 (5.9%)
Zidovudine/Lamivudine/Efavirenz 11 (5.5%) 7 (6.9%) 4 (4.0%)
Zidovudine/Lamivudine/Nevirapine 24 (11.9%) 11 (10.9%) 13 (12.9%)
Stavudine/Lamivudine/Efavirenz 1 (0.5%) 1 (1.0%) 0 (0%)
Other 2 (1.0%) 1 (1.0%) 1 (1.0%)
Second Line ART Regimen, n (%) 60 (29.7%) 32 (31.7%) 28 (27.7%)
Tenofovir/Lamivudine/Atazanavir/Ritonavir 33 (16.3%) 17 (16.8%) 16 (15.8%)
Zidovudine/Lamivudine/Atazanavir/Ritonavir 9 (4.5%) 6 (5.9%) 3 (3.0%)
Zidovudine/Lamivudine/Lopinavir/Ritonavir 2 (1.0%) 0 (0%) 2 (2.0%)
Abacavir/Lamivudine/Atazanavir/Ritonavir 9 (4.5%) 4 (4.0%) 5 (5.0%)
Abacavir/Lamivudine/Lopinavir/Ritonavir 7 (4.0%) 5 (5.0%) 2 (2.0%)